Highest-materiality recent filing
HeartBeam finalizes separation with former officer Robert P. Eno; $300K cash, equity acceleration
Robert P. Eno's employment terminated June 30, 2026; separation agreement executed July 30, 2026.
HeartBeam receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on June 30, 2026 for non-compliance with minimum bid price of $1.00 per share.
HeartBeam announces strategic shift to license 3D ECG tech; CEO Eno departs, Vajdic takes PEO role
CEO Robert Eno and board mutually agreed to his departure effective June 30, 2026; he will remain as a consultant.
HeartBeam grants 2.8M PRSUs to President Vajdic; approves transaction bonus on change in control
2,800,000 performance-based RSUs granted to President/Founder Branislav Vajdic under 2022 Equity Incentive Plan.
HeartBeam closes $10M public offering of 12.5M shares at $0.80 per share
Issued 12.5M shares at $0.80, gross proceeds $10M; underwriter option for 1.875M additional shares.
HeartBeam receives FDA NSE letter for 12-Lead ECG Synthesis 510(k), will seek resolution
FDA issued a Not Substantially Equivalent (NSE) letter for HeartBeam's 12-Lead ECG Synthesis Software 510(k) on Nov 20, 2025.
HeartBeam auditor resigns; CBIZ CPAs engaged; going concern noted
Marcum LLP resigned as auditor on April 21, 2025, due to CBIZ CPAs acquiring its attest business.
HeartBeam prices $10M public offering of 5.88M shares at $1.70 per share
Offering of 5,882,353 shares of common stock at $1.70/share; gross proceeds ~$10M.
HeartBeam appoints Robert Eno as CEO; founder Vajdic moves to President
Robert Eno named CEO effective Oct 21, 2024; base salary of $400,000 with 60% incentive bonus.
HeartBeam appoints Timothy Cruickshank as CFO; base salary $385K plus equity
Timothy Cruickshank appointed CFO effective September 9, 2024.
HeartBeam enters $17M at-the-market equity facility with Public Ventures, terminates prior AGP deal
New ATM sales agreement with Public Ventures allows sale of up to $17M of common stock at 3% commission.
HeartBeam CFO Richard Brounstein retires effective Feb 1, 2024; no successor named
Richard Brounstein retired as CFO effective February 1, 2024; he served since 2015.
HeartBeam regains Nasdaq compliance with $23.2M equity offering of 16.67M shares
Received Nasdaq deficiency notice for stockholders' equity below $2.5M on Mar 20, 2023.
HeartBeam raises ~$1.4M in registered direct offering of 1M shares at $1.50/sh
Sold 1,000,000 shares of common stock at $1.50/share to an accredited investor.
HeartBeam closes $25M secondary offering; shifts commercial launch to 2024
Offering of 16.67M shares at $1.50/share closed on May 2, 2023; net proceeds $23.2M.
HeartBeam receives Nasdaq deficiency notice for failing minimum $2.5M equity requirement
Reported stockholders' equity of $2.374M as of Dec 31, 2022, below the $2.5M minimum.
HeartBeam launches $15M public offering; reports positive trial results for portable 12-lead ECG
$15M public offering of common stock; proceeds for clinical/reg ($2M), R&D ($7M), sales/mkt ($1M), G&A ($5M).
HeartBeam amends financing agreements, reducing available equity and note amounts to $4M each
Amended Securities Purchase Agreement with Maverick Capital reduces total common stock available from $5M to $4M.
HeartBeam enters up to $10M equity and convertible note facility with Maverick Capital
Up to $5M common stock at 75% of VWAP; initial $500K drawdown on 6% convertible note issued March 1, 2023.
HeartBeam enters into $13M at-the-market equity sales agreement with A.G.P.
Up to $13M of common stock may be sold through A.G.P. in at-the-market offerings under existing S-3.
HeartBeam appoints Robert Eno as President effective Jan 18, 2023
Robert Eno appointed as President effective Jan 18, 2023, a newly created role.
Five-phase expedited project includes device builds for verification, validation, packaging and manufacturing transfer.
HeartBeam partners with LIVMOR for RPM platform; terminates Ximedica deal
Partnered with LIVMOR to build HeartBeam-branded version of LIVMOR's FDA-cleared Halo+ RPM portal for physicians and patients.
HeartBeam appoints Alan Baumel as COO effective Dec 20, 2021
Annual salary of $200,000, bonus eligibility post-IPO, and option for 1% of post-IPO shares.
HeartBeam completes $16.5M IPO; net proceeds $14.9M for ECG product development
IPO of 2.75M units at $6/unit; each unit includes one share and one warrant exercisable at $6 for 5 years.
On June 18, 2026, Heartbeam, Inc. (the “Company”) and Mr. Eno mutually agreed to his departure as the Company’s Chief Executive Officer, as a member of the Company’s Board of Directors (the “Board”), and as the Company’s principal executive officer, effective as of June 30, 2026
On June 18, 2026, Mark Strome notified the Company of his resignation from the Board and all committees thereof, effective immediately.
Dr. Vajdic, will also serve as the Company’s principal executive officer, effective July 1, 2026.
appointed Robert Eno, the Company’s Chief Executive Officer, as a member of the Board effective as of May 5, 2025
the Board appointed Branislav Vajdic, PhD, Founder and current Chief Executive Officer as President of the Company (the “President Appointment”) effective as of October 21, 2024.
On October 17, 2024, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) appointed Robert Eno as Chief Executive Officer of the Company (the “CEO Appointment”) effective as of October 21, 2024.
On August 22, 2024, the Board of Directors (the “ Board ”) of HeartBeam, Inc. (the “ Company ”) appointed Timothy Cruickshank as Chief Financial Officer of the Company (the “ Appointment ”) effective as of September 9, 2024.
On December 29, 2023, Richard Brounstein, informed the Company of his plans to retire from his position (the “ Retirement ”) as Chief Financial Officer of HeartBeam, Inc. (the “ Company ” or " HeartBeam ") effective as of February 1, 2024.
On July 24, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Michael R. Jaff as a director of the Company (the “Appointment”) effective as of July 24, 2023.
On June 5, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Mark Strome and Ken Nelson as directors of the Company (the “Appointments”) effective as of June 5, 2023.
Additionally, Mr. Brounstein, the Company’s Chief Financial Officer, announced plans to retire and his resignation will be effective October 31, 2023.
On June 5, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Mark Strome and Ken Nelson as directors of the Company (the “Appointments”) effective as of June 5, 2023.
Max materiality 0.95 · Median 0.60 · Most common event other_material